Biopharma M&A + Investment During a Downturn: Applying Modern Market Intelligence and Innovative Strategies
Wednesday 22nd February
3pm-4pm GMT
A panel discussion with:
- Matthias Muellenbeck, SVP, Head of Global Business Development & Alliance Management, Merck KGaA
- Stephanie Sirota, Partner & Chief Business Officer, RTW Investments
- Ed Kivell, VP of Global Strategic Accounts EMEA/APAC, AlphaSense
- Michael Margolis, Senior Managing Director, Co-Head of Healthcare Investment Banking, Oppenheimer & Co.
After a difficult 2022 for the life sciences industry, as we enter 2023 what are expectations for the investment, deal-making and M&A landscape? How best can the industry innovate and apply modern market intelligence and new strategies for the year ahead?
- Factors influencing Biopharma M&A and investment activity during economic downturns
- Applying modern market intelligence in biopharma M&A and investing
- How have data sources for deal flow evolved in recent years?
- Practising modern market intelligence
- Identifying and completing investment and M&A deals
- How winners innovate - doubling down in a downturn
Staying up to date on clinical trial pipelines, evolving markets, disease areas, and BD&L opportunities is highly time-consuming and fragmented. AlphaSense ensures you find the information you need faster and before it’s on anyone else’s radar.
